PFE
Pfizer’s obesity bet is still alive
Pfizer dropped new Phase 2b data on berobenatide, its investigational GLP-1 receptor agonist for weight management, and the headline number is pretty eye-catching: participants saw a non-placebo-adjusted weight loss of 15.9% after 32 weeks. That’s the kind of number that gets Wall Street leaning in, even if it doesn’t immediately send confetti flying.
Why investors are paying attention
The obesity drug market is turning into the pharma version of a celebrity casting call — everyone wants a role, and the competition is brutal. Pfizer says the pivotal Phase 3 study is already open for enrollment, and it’s planning 10 Phase 3 studies in 2026 across chronic weight management and obesity-related comorbidities like knee osteoarthritis and sleep apnea.
That matters because obesity drugs aren’t just about weight loss anymore. They’re about becoming the prescription equivalent of a Swiss Army knife: one therapy, multiple potential uses, lots of revenue paths.
The other Pfizer headline
There was also a separate FDA win in the same story: HYMPAVZI picked up an expanded indication for certain hemophilia A and B patients, including pediatric patients ages 6 to 11. Nice day for the pipeline, even if the stock still finished down about 1% as investors digested the obesity data.
Big picture: Pfizer is still trying to prove it can build a next-wave growth engine outside the old-school blockbuster playbook. Berobenatide is another swing at that prize — and the market will keep score on the next readout, not just the hype reel.